The 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Adam J. Fein, Ph.D.
Drug Channels Institute

March 2021

Full report available at https://drugch.nl/pharmacy
COPYRIGHT

Copyright © 2021 by Pembroke Consulting, Inc., d/b/a Drug Channels Institute. All rights reserved.

This report is protected by copyright law and may not be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed, or resold, in whole or in part, in any form or manner or by any means whatsoever, by any person without prior written consent. This report may be cited in commercial documents with full and appropriate attribution. This report is for informational purposes only and is provided “as is” without any express or implied warranty. The analyses in this report are based solely on information and data that are in the public domain. All conclusions, findings, opinions, and recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by Pembroke Consulting, Inc., Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and Pembroke Consulting, Inc., and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. Pembroke Consulting, Inc., and Drug Channels Institute do not make investment recommendations in this report or otherwise. Nothing in this report should be interpreted as an opinion by Pembroke Consulting, Inc., Drug Channels Institute, or the author on the investment prospects of specific companies.

Drug Channels® is a registered trademark of Pembroke Consulting, Inc.
LICENSE TERMS

This report is protected by copyright law. Unauthorized reproduction or distribution of this report or any portion of it may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. Nothing in the license is intended to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws.

If you would like to quote from or otherwise cite the report, here is a suggested sample citation:


The complete End User License Agreement is available at: http://drugch.nl/2021EULA
ABOUT THE AUTHOR

Adam J. Fein, Ph.D., is the CEO of Drug Channels Institute (DCI), a leading management educator for and about the pharmaceutical industry. DCI is a subsidiary of Pembroke Consulting, Inc.

Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as The Wall Street Journal, The New York Times, The Washington Post, Forbes, and many others.

His popular and influential Drug Channels website is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. Drug Channels is the only place where you’ll find a serious discussion of PBMs, drug pricing, and pharmacy economics, all explained with humor and a healthy dose of pop culture.

Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and his undergraduate degree from Brandeis University. He lives in Philadelphia with his wife and business partner, Paula.

Contact information
Adam J. Fein, Ph.D.
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700
Website: www.DrugChannelsInstitute.com
Email: afein@drugchannels.net

Visit Dr. Fein’s Drug Channels website for the latest industry updates!

www.DrugChannels.net
ABOUT DRUG CHANNELS INSTITUTE

Drug Channels Institute (DCI), a division of Pembroke Consulting, Inc., is a leading provider of specialized management education for and about the pharmaceutical industry.

Drug Channels Institute combines Dr. Fein’s expertise and cutting-edge analysis—such as this 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers—into interactive e-learning modules that offer your team a thorough grounding in crucial industry topics. Click here to view a module list.

These online learning tools explain highly complex economic and business data and concepts so you can:

- Make better decisions to achieve your business goals
- Improve relationships with key accounts
- Understand your customers, channels, and the economics of the U.S. pharmaceutical industry

Drug Channels Institute also hosts live video webinars during which Dr. Fein discusses trends and policies that affect the pharmaceutical industry and its channels. Click here to view our current and previous video webinars.

To learn more about how Drug Channels Institute can help your business, please contact:

Paula Fein, M.S.Ed.
V.P., Business Development
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700 x11
Website: www.drugchannelsinstitute.com
Email: paula@drugchannels.net
INTRODUCTION AND GUIDE TO THE 2021 REPORT


However, this period also demonstrated the underlying resilience of U.S. distribution and dispensing channels for prescription drugs. Pharmaceutical wholesalers maintained shipments and operational capacity. Payers and pharmacy benefit managers (PBMs) waived benefit limitations so patients could access therapies. Pharmacies and pharmacists stepped up as critical providers of medications and are playing a crucial role in administering COVID-19 vaccines.

In the midst of the pandemic, the industry continues to confront a diverse set of commercial, political, and legal challenges. They are among the many issues we consider in this report:

- Total prescription dispensing revenues of retail, mail, long-term care, and specialty pharmacies reached a record $465 billion in 2020. Specialty drugs accounted for nearly 40% of these revenues—and an even greater share of payer’s net prescription costs.

- Insurers, PBMs, and specialty pharmacies have combined into vertically integrated organizations. The COVID-19 pandemic has slowed or delayed some companies’ efforts to achieve vertical synergies. However, these organizations are still poised to exert greater control over patient access, sites of care, dispensing locations, and pricing.

- Payers and PBMs are tightening their management of specialty drugs, thereby pressuring independent specialty pharmacies, physician practices, and hospitals. The specialty pharmacy industry has become more concentrated, due to the acquisition of many large independent specialty pharmacies.

- List prices for brand-name drugs—which directly impact the revenues and profits of pharmacies and PBMs—are growing more slowly than they have historically. However, brand-name drugs’ net prices (after rebates and discounts) have declined for the third year. Consequently, growth in the number of people being treated and the number of prescriptions being dispensed has become a key driver of rising drug spending.

- Generic market pricing has stabilized since the periods of rapid inflation and deflation. Pharmacy profits have benefited from this stability, though low generic prices are limiting pharmacies’ revenues and gross profits from these prescriptions.

- The pharmacy industry remains intensely competitive, pressuring prescription profits. Retail pharmacies are undergoing a shakeout that is reducing the number of U.S. pharmacy locations, as small chains and supermarkets sell to larger competitors.
• Patients taking specialty drugs faced high out-of-pocket costs due to benefit design that favors deductibles and coinsurance spending. At the same time, a growing share of prescriptions is being dispensed with no patient out-of-pocket expense.

• Controversy over copay accumulator and maximizer programs is rising, as plans attempt to reduce their spending by accessing manufacturers’ patient support funds.

• The gross-to-net bubble, which measures total rebates and discounts paid by manufacturers, reached $187 billion for patent-protected brand-name drugs in 2020. Regulatory efforts to remove the role of rebates in the Medicare Part D program have been delayed, perhaps indefinitely.

• Regulators and lawmakers continue to scrutinize PBMs’ profit models and incentives. Disclosures about PBMs’ unexpectedly large profits in Managed Medicaid programs have triggered several larger states to carve-out pharmacy to fee-for-service Medicaid.

• The 340B Drug Pricing Program is now roughly the size of the nation’s Medicaid outpatient drug market. Pharmacies’ role in—and profits from—the 340B program were disrupted during 2020 when some manufacturers began limiting prescriptions dispensed via contract pharmacies. These highly controversial actions have triggered litigation and raised the prospect of greater government oversight of 340B.

• Amazon’s pharmacy strategy has become clearer, though the company is still not poised to fundamentally disrupt the existing drug channel. Venture capital firms expanded their financing of numerous digital pharmacies that are attempting to alter conventional ways of doing business.

• The retail pharmacy clinic model is fading in favor of locations with broader healthcare services. Pharmacies are competing more directly with urgent care clinics and other healthcare providers.

• The federal government has finalized regulations for the commercial importation of drugs intended for Canada. However, industry opposition and practical challenges seem likely to limit any impact on pharmacies, PBMs, and U.S. drug prices.

• Federal legislative action regarding drug prices remains highly uncertain. However, states have already enacted a total of more than 160 laws targeting various aspects of the U.S. drug channel and its participants.

• New cell and gene therapies have been launched. Specialty pharmacies that are not owned or closely affiliated with a payer seem likely to play a limited role in these emerging distribution and reimbursement channel models.
Understanding an Evolving Marketplace

The 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers—our 12th edition—remains the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing, reimbursement, and dispensing system. This unique resource is your ultimate guide to the complex web of interactions within U.S. prescription drug channels.

This definitive, nonpartisan resource includes the most current information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, government regulations, and more. The report synthesizes a wealth of statistical data, research studies, financial information, and my own unique business consulting experience. It will aid pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospital executives, pharmacy buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and many others.

Thousands of companies operate within the U.S. system, enabling more than 6.1 billion equivalent prescriptions to be dispensed and paid. The table below highlights the largest public companies that operate in the drug channel. Many of these firms are among the largest businesses on the Fortune 500 list.

Major Public Companies Operating in U.S. Drug Channels

<table>
<thead>
<tr>
<th>Company</th>
<th>Stock Ticker</th>
<th>Primary U.S. Channel Role(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amazon</td>
<td>AMZN</td>
<td>Mail pharmacy</td>
</tr>
<tr>
<td>CVS Health</td>
<td>CVS</td>
<td>Insurer/PBM/Chain drugstore/Mail &amp; specialty pharmacy/long-term care pharmacy</td>
</tr>
<tr>
<td>GoodRx</td>
<td>GDRX</td>
<td>Discount card provider</td>
</tr>
<tr>
<td>Kroger</td>
<td>KR</td>
<td>Supermarket with pharmacy/PBM/ Specialty pharmacy</td>
</tr>
<tr>
<td>Rite Aid Corporation</td>
<td>RAD</td>
<td>Chain drugstore/PBM/Mail &amp; specialty pharmacy</td>
</tr>
<tr>
<td>Walgreens Boots Alliance</td>
<td>WBA</td>
<td>Chain drugstore/Mail &amp; specialty pharmacy/long-term care pharmacy</td>
</tr>
<tr>
<td>Walmart Stores, Inc.</td>
<td>WMT</td>
<td>Mass merchant with pharmacy/Specialty pharmacy</td>
</tr>
<tr>
<td>Anthem</td>
<td>ANTM</td>
<td>Insurer/PBM</td>
</tr>
<tr>
<td>Centene</td>
<td>CNC</td>
<td>Insurer/PBM/Mail &amp; specialty pharmacy</td>
</tr>
<tr>
<td>Cigna</td>
<td>CI</td>
<td>Insurer/PBM/Mail &amp; specialty pharmacy</td>
</tr>
<tr>
<td>Humana</td>
<td>HUM</td>
<td>Insurer/PBM/Mail &amp; specialty pharmacy</td>
</tr>
<tr>
<td>UnitedHealth Group</td>
<td>UNH</td>
<td>Insurer/PBM/Mail &amp; specialty pharmacy</td>
</tr>
<tr>
<td>AmerisourceBergen</td>
<td>ABC</td>
<td>Pharmaceutical wholesaler/Specialty pharmacy</td>
</tr>
<tr>
<td>Cardinal Health</td>
<td>CAH</td>
<td>Pharmaceutical wholesaler</td>
</tr>
<tr>
<td>McKesson Corporation</td>
<td>MCK</td>
<td>Pharmaceutical wholesaler/Specialty pharmacy</td>
</tr>
</tbody>
</table>

PBM = pharmacy benefit manager  
Source: Drug Channels Institute research

These and other companies discussed in this report operate within a complex distribution, payment, and reimbursement system, illustrated on the next page.
The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-Name Drugs

Product Movement, which traces shipments from pharmaceutical manufacturers to the drug wholesalers that supply pharmacies. Retail, mail, long-term care, and specialty pharmacies mark the final step in which a prescription is dispensed to a patient.

Financial Flows, which transfer money from third-party payers to pharmacy benefit managers (PBMs), which in turn reimburse pharmacies. Funds flow to manufacturers via pharmacies, which purchase drugs from wholesalers. Funds flow from manufacturers to PBMs in the form of rebates and fees. The PBMs share most of these payments with plan sponsors, reducing plans’ net prescription costs. Manufacturers’ payments to PBMs and other third-party payers do not flow through wholesale or retail channels.

Contractual Relationships, which govern the relationships between: 1) payers and PBMs; 2) PBMs and pharmacies; 3) pharmacies and wholesalers; 4) wholesalers and manufacturers; and 5) manufacturers and PBMs.

In Sections II and III of the report, we revisit this chart to link each flow with the corresponding report chapters that explain and analyze it. To further explain these flows and their corresponding report chapters, the chart appears as Exhibit 66 (page 108).
What’s New in the 2021 Report

The 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers retains the overall structure we employed in last year’s edition. As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs.

The most notable new material throughout this 2021 edition addresses COVID-19 and its impact on the pharmacy and PBM industries. Given the uncertainty, we plan to revisit this topic in future editions. We will also continue to monitor these trends on Drug Channels.

Many sections and chapters have been expanded and/or reorganized to better cover the latest industry developments. Changes and updates in this 2021 edition include:

- Chapter 1 includes new material about healthcare and clinical services at retail locations as well as additional data about vaccine and immunization services.
- Chapter 2 incorporates new data analyses that address COVID-19 and its impact on the pharmacy industry.
- We have further expanded and updated our Chapter 3 analyses of the specialty market, including additional information about PBMs, hospitals, and specialty hubs.
- Chapter 4 includes new estimates of health insurance coverage and our projections of how COVID-19 will alter these figures. We also incorporate CMS’s comprehensive revision to national healthcare spending data, including outpatient prescription drugs.
- Section 4.3. has been split into two sections to better cover the cash-pay prescription market and the role of discount cards.
- Chapter 5 expands our coverage of PBMs to include additional market participants. We have also updated and expanded our analyses of spread pricing in Managed Medicaid.
- In Chapter 6, the data on patient out-of-pocket expenses include new information on cost sharing, coinsurance, and average out-of-pocket spending.
- Chapter 8 contains new material discussing the differences between pharmacy reimbursement under fee-for-service and managed care approaches in Medicaid.
- Chapter 9 offers a new section on pricing for the Department of Veterans Affairs.
- Chapter 11 includes significant new information about pharmacies’ profits from the 340B Drug Pricing Program.
Chapter 12, which covers the industry outlook and emerging trends, has been significantly updated to reflect developments that have occurred since the preceding edition of this report.

Throughout the report, we have added new industry data sources, deepened our coverage of many topics, and added more trending information. There are 211 exhibits in the 2021 edition, compared with 203 in the 2020 edition and 180 in the 2019 edition.

Structure of the 2021 Report

This report analyzes the industry in 3 major sections, comprising 12 total chapters:

SECTION I: THE U.S. PHARMACY INDUSTRY

- **Chapter 1: Industry Overview** (page 10) defines the industry and its regulatory framework, describes the different products and prescriptions that a pharmacy dispenses, provides data on traditional and specialty prescription costs, delineates among different pharmacy industry participants, and quantifies differences among dispensing formats. This chapter includes our analysis of pharmacist-provided clinical services (including medication therapy management services) and healthcare clinics.

- **Chapter 2: Pharmacy Industry Market Structure** (page 44) analyzes the industry’s prescription and revenue growth trends. It identifies the largest pharmacies based on prescription revenues. It then analyzes recent market share trends for each dispensing format and for the major national companies.

- **Chapter 3: Specialty Drugs and Specialty Pharmacies** (page 67) provides a comprehensive overview of the pharmacies dispensing specialty medications. It includes our exclusive analyses of national market share for pharmacy-dispensed specialty drugs and accreditation trends among pharmacies. It also provides a competitive analysis of the various organizations that compete to dispense specialty medications. The chapter reviews the channel strategies that pharmaceutical manufacturers use for specialty drugs, explains the role of service fees, and profiles the specialty hub services market.

SECTION II: THIRD-PARTY PAYMENT AND PHARMACY BENEFITS

- **Chapter 4: Payment and Spending for Prescription Drugs** (page 109) examines the primary payers for prescription drugs at retail, mail, long-term care, and specialty pharmacies. It analyzes recent changes in the payer mix and spending on traditional vs. specialty drugs. Chapter 4 also reviews the cash-pay prescription market and the use of discount card programs.

- **Chapter 5: Pharmacy Benefit Management** (page 133) identifies the services and roles of pharmacy benefit managers (PBMs). Chapter 5 also analyzes the structure of the PBM
industry and reviews the business strategies of the largest PBMs. It describes the relationship between PBMs and the pharmacies that participate in a PBM’s network, reviews how pharmacy services administrative organizations (PSAOs) intermediate between retail pharmacies and PBMs, and explains how plan sponsors compensate PBMs for benefit management services. Chapter 5 includes a detailed review of PBMs’ spread pricing profits from Managed Medicaid programs. This material appeared in Chapter 11 of the 2020 edition.

• **Chapter 6: Consumer Copayments and Coinsurance** (page 166) analyzes the benefit designs and plan structures that determine patients’ out-of-pocket spending for the major third-party payers: employer-sponsored health plans, Health Insurance Marketplace (HIM) plans, Medicare Part D, and Medicaid. We explore manufacturers’ out-of-pocket payment support programs, explain the emergence and use of copay accumulators and maximizers, and provide data on patient out-of-pocket expenses. We also explore how benefit design affects patients’ costs.

• **Chapter 7: Narrow Pharmacy Networks** (page 203) analyzes the structure, utilization, and economics of narrow network models. We explain the use and economics of narrow networks for pharmacies in commercial health plans and Medicare Part D. We review mail and retail pharmacies as narrow network options for maintenance prescriptions. This chapter also evaluates the latest data on payer-defined networks for specialty drug dispensing in commercial health plans and for buy-and-bill channels.

**SECTION III: DRUG CHANNEL ECONOMICS AND OUTLOOK**

• **Chapter 8: Prescription Reimbursement by Third-Party Payers** (page 227) explains the formulas and methodologies for computing a pharmacy’s revenue from brand-name, generic, and specialty prescriptions. It also delves into maximum allowable cost (MAC) prices as well as the regulations and laws related to MAC prices. This chapter compares traditional list price methods with acquisition-cost reimbursement approaches now utilized in fee-for-service Medicaid programs. We also review the economics of mail vs. retail pharmacies for payers and consumers.

• **Chapter 9: Drug Pricing, Rebates, and Payer Costs** (page 242) explores rebates in commercial health plans, Medicare Part D, Medicaid, and the Department of Veterans Affairs. It explains how PBMs negotiate with manufacturers, analyzes trends in list and net drug prices, and describes the gross-to-net bubble phenomenon. The chapter explains how plan sponsors use rebates, the role of point-of-sale rebates, and controversies over rebates. The chapter concludes by illustrating how prescription reimbursement, formulary rebates, and consumer copayments affect a plan sponsor’s net costs for a typical traditional and specialty prescription.

• **Chapter 10: Relationships With Pharmaceutical Wholesalers** (page 275) explores pharmacies’ interactions with their primary wholesale suppliers of drugs. It explains
wholesalers’ channel roles and services, identifies the largest wholesale suppliers, and analyzes how wholesalers affect pharmacies’ acquisition costs for drugs. We present our latest data on pharmacy group purchasing organizations and the generic sourcing relationships between wholesalers and large pharmacies.

- **Chapter 11: Pharmacy and Prescription Profitability** (page 287) unites the reimbursement and cost discussion from Chapter 8 and Chapter 10 by presenting the latest available data on pharmacy and prescription profitability. This chapter documents overall drugstore profitability, pharmacy margins for prescriptions from different dispensing formats, profit differences between brand and generic prescriptions, and PBMs’ gross profits from network and mail pharmacies. Chapter 11 also includes material on the direct and indirect remuneration (DIR) fee payments that pharmacies make to PBMs and health plans. Finally, we consider pharmacies’ role and profits in the 340B Drug Pricing Program.

- **Chapter 12: Outlook and Emerging Trends** (page 322) presents the outlook for net prescription drug spending and our updated projections for the pharmacy industry’s product mix and revenues in 202. This chapter also considers future trends, including pharmacy-dispensed biosimilars, importation, state and federal legislation, cell and gene therapies, and such new entrants as Amazon and venture-backed startup pharmacies.

**How to Use the 2021 Report**

*The chapters are self-contained and do not need to be read in order.* We include extensive internal clickable hyperlinks to help you navigate the entire document and customize it to your specific needs. After clicking a link, use the following shortcuts to return to your previous location in the document:

- **Windows:** ALT+Left Arrow
- **Mac:** Command+Left Arrow

There are more than 700 endnotes, most of which have hyperlinks to original source materials. The report also includes a list of the Acronyms and Abbreviations used within it. To search the entire PDF document for every occurrence of a word or phrase, use the following shortcuts:

- **Windows:** Shift+CTRL+F
- **Mac:** Shift+Command+F

As always, I welcome your feedback. Please contact me if you have any questions or comments about *The 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers*.

Adam J. Fein
March 2020

P.S. [Click here for post-publication errata.](#)
## CONTENTS

**PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES**  ........................................................................................................ 1

**SECTION I: THE U.S. PHARMACY INDUSTRY** ....................................................................................................................... 9

**Chapter 1: Industry Overview** ................................................................................................................................................. 10

1.1. Pharmacy Fundamentals ......................................................................................................................................................... 10

1.1.1. Defining the Practice of Pharmacy ............................................................................................................................ 10

1.1.2. Pharmacies and the Drug Supply Chain Security Act ................................................................................................. 11

1.2. The Products That Pharmacies Dispense ......................................................................................................................... 15

1.2.1. Brand vs. Generic Drugs ................................................................................................................................................. 15

1.2.2. Traditional vs. Specialty Drugs ...................................................................................................................................... 18

1.2.3. Top Therapy Classes and Average Prescription Costs ................................................................................................. 21

1.3. Pharmacy Industry Participants ........................................................................................................................................ 23

1.3.1. Pharmacy Dispensing Formats .................................................................................................................................. 23

1.3.2. Differences Among Outpatient Retail Dispensing Formats .......................................................................................... 24

1.3.3. Pharmacist Salaries and Employment .......................................................................................................................... 29

1.4. Healthcare and Clinical Services .................................................................................................................................. 32

1.4.1. Retail Clinics and Healthcare Services ......................................................................................................................... 32

1.4.2. Medication Therapy Management (MTM), Clinical Services, and Provider Status .................................................... 36

1.4.3. Immunization and Vaccination .................................................................................................................................. 41

**Chapter 2: Pharmacy Industry Market Structure** ................................................................................................................. 44

2.1. Industry Trends .................................................................................................................................................................... 44

2.1.1. Total and 30-Day Equivalent Prescriptions .................................................................................................................. 44

2.1.2. Prescription Dispensing Revenues ................................................................................................................................ 47

2.2. National Prescription Dispensing Market Share, by Company ............................................................................................ 48

2.3. Trends by Dispensing Format ......................................................................................................................................... 50

2.3.1. Long-Term Trends in Revenues and Prescriptions ...................................................................................................... 50

2.3.2. Market Changes in 2020 ................................................................................................................................................. 51

2.3.3. National Retail Chains ...................................................................................................................................................... 54

2.3.4. Regional Chains ............................................................................................................................................................... 59

2.3.5. Independent Pharmacies ............................................................................................................................................... 61
6.2.3. Patient Assistance Programs ................................................................. 191
6.3. Out-of-Pocket Expenses ........................................................................ 192
6.3.1. Actual Patient Out-of-Pocket Spending on Prescriptions ...................... 192
6.3.2. Consequences of Pharmacy Benefit Designs ...................................... 196

Chapter 7: Narrow Pharmacy Networks ................................................... 203
7.1. Overview of Pharmacy Benefit Network Models .................................... 203
7.1.1. Network Options .............................................................................. 203
7.1.2. The Economics of Narrow Pharmacy Networks .................................. 205
7.1.3. Legal and Regulatory Restrictions on Network Design ......................... 206
7.2. Retail Pharmacy Networks .................................................................... 208
7.2.1. Preferred Retail Networks in Medicare Part D .................................... 208
7.2.2. Narrow Retail Networks in Commercial and Other Plans .................. 215
7.2.3. Narrow Networks for Maintenance Prescriptions ............................ 217
7.3. Payer-Defined Specialty Dispensing Networks ...................................... 220
7.3.1. Commercial Health Plans ................................................................ 220
7.3.2. Specialty Pharmacies’ Role in Buy-and-Bill Channels ....................... 222

SECTION III: DRUG CHANNEL ECONOMICS AND OUTLOOK ..................... 226

Chapter 8: Prescription Reimbursement by Third-Party Payers ..................... 227
8.1. The Basics of Prescription Reimbursement ........................................... 227
8.1.1. Estimated Acquisition Cost (EAC) ..................................................... 227
8.1.2. Dispensing Fees .............................................................................. 229
8.1.3. Service and Data Fees .................................................................... 230
8.2. Reimbursement for Brand-Name and Specialty Prescriptions .................. 230
8.2.1. Wholesale Acquisition Cost (WAC) and Average Wholesale Price (AWP) List Prices ........ 230
8.2.2. AWP Discounts for Pharmacy Reimbursement .................................. 231
8.2.3. Why Mail Pharmacies Accept Lower Reimbursements ....................... 234
8.3. Reimbursement for Generic Prescriptions ............................................. 235
8.3.1. AWP Discounts for Generic Prescriptions ........................................ 235
8.3.2. Maximum Allowable Cost (MAC) Limits and Generic Effective Rate (GER) .................. 236
8.3.3. Regulations and Laws Regarding MAC Limits .................................... 237
8.3.4. Medicaid and Federal Upper Limits ............................................... 238
12.4.5. Controversy Over the 340B Program and Recent Manufacturer Actions .......................... 346
12.5. New Entrants and Potential Pharmacy Market Disruption.................................................. 349
  12.5.1. Update on Amazon’s Potential Impact ........................................................................... 349
  12.5.2. Venture-Backed Digital Pharmacies ............................................................................... 351

Acronyms and Abbreviations........................................................................................................ 355
Endnotes ......................................................................................................................................... 356
LIST OF EXHIBITS

Exhibit 1: Timeline of DSCSA Requirements for Pharmacies (Dispensers), 2013 to 2023 .............................................12
Exhibit 2: Unbranded and Branded Generics, Share of U.S. Prescriptions, 2003 to 2025 ..................................................15
Exhibit 3: Variation in State Generic Substitution Policies, 2020 ..................................................................................16
Exhibit 4: Top Traditional Therapy Categories, Generic Drugs As a Share of Prescriptions and Net Spending, 2019.17
Exhibit 5: Specialty Prescriptions, Number and Share of Total, 2015 to 2020 .................................................................18
Exhibit 6: Top Specialty Therapy Categories, Generic Drugs As a Share of Prescriptions and Net Spending, 2019 ....21
Exhibit 7: Top Traditional Therapy Categories, Share of Net Spending, and Average Net Prescription Costs, 2019 ..22
Exhibit 8: Top Specialty Therapy Categories, Share of Net Spending, and Average Net Prescription Costs, 2018 .....22
Exhibit 9: Chain Drugstore Revenues, by Type of Merchandise, 2017 ..............................................................................25
Exhibit 10: Average Annual Number of Prescriptions per Pharmacy, by Retail Dispensing Format, 2020 ..........26
Exhibit 11: Average Wait Time for Prescription Pickup, by Retail Dispensing Format, 2020 .................................26
Exhibit 12: Average Annual Prescription Revenue per Pharmacy Outlet, by Retail Dispensing Format, 2020 ......27
Exhibit 13: Top Four Reasons for Pharmacy Selection, by Dispensing Format, 2020 .........................................................28
Exhibit 14: Customer Satisfaction With Pharmacies, by Dispensing Format and Company, 2020 .................................28
Exhibit 15: Pharmacist Employment and Salary, by Practice Setting, 2019 .................................................................29
Exhibit 16: Share of Pharmacist Employment, by Industry, 2013 vs. 2019 .................................................................30
Exhibit 17: Pharmacists and Healthcare Workers, Change in Annual Average Salary, by Employer, 2014 to 2019...31
Exhibit 18: Pharmacist Employment, by Industry and Dispensing Format, 2019 vs. 2029 .................................................32
Exhibit 19: Insurance Coverage for Retail Clinics, 2010 to 2020 ..................................................................................33
Exhibit 20: Number of U.S. Retail Clinics, 2004 to 2021 ...............................................................................................34
Exhibit 21: Providers of Medication Therapy Management Services, Medicare Part D, 2015 vs. 2019 .................38
Exhibit 23: CPESN Networks and Pharmacies, 2018 to 2020 .........................................................................................40
Exhibit 24: Sites of Vaccine Administration for Medicare Beneficiaries, 2018 .................................................................41
Exhibit 25: Adult Influenza Vaccination, by Place of Vaccination, 2018-19 vs. 2020-21 ...............................................42
Exhibit 26: Pharmacy Availability and Consumer Usage of Immunization, by Dispensing Format, 2016 vs. 2020 .....43
Exhibit 27: Total U.S. Pharmacy Industry Prescription Revenues, Prescriptions, and Locations, by Dispensing Format, 2020 .................................................................44
Exhibit 28: Prescriptions, Annual Total and Growth, 2017 to 2020 ..............................................................................45
Exhibit 29: 30-Day Equivalent Prescriptions, Annual Total and Growth, 2017 to 2020 ...........................................46
Exhibit 30: 90-Day Prescriptions As a Percentage of Total Prescriptions, by Dispensing Format, 2017 to 2020 ......46
Exhibit 31: Pharmacy Industry Prescription Revenues, Annual Total and Growth, 2015 to 2019 .................................48
Exhibit 32: Largest 10 U.S. Pharmacies, by Total Prescription Revenues, 2020 ...........................................................49
Exhibit 33: Total Change in 30-Day Equivalent Prescriptions Dispensed and Prescription Revenues, by Pharmacy Type, 2013 vs. 2020 .................................................................50
Exhibit 34: 30-Day Equivalent Prescriptions Dispensed per Location, by Dispensing Format, 2010 to 2020

Exhibit 35: Year-over-Year Change in Weekly Number of 30-Day Equivalent Prescriptions Dispensed, January to December 2020

Exhibit 36: Number of 30-Day Equivalent Prescriptions, by Dispensing Format, 2019 vs. 2020

Exhibit 37: Prescription Dispensing Revenues, by Dispensing Format, 2019 vs. 2020

Exhibit 38: Year-Over-Year Change in Same-Store Prescription Count, by Chain, 2016 to 2020

Exhibit 39: Walgreens Boots Alliance, U.S. Store Count, 2016 to 2020

Exhibit 40: Largest Regional Chain Drugstores, by Total Prescription Revenues, 2020

Exhibit 41: Pharmacy Locations Acquired, by Company, 2010 to 2020

Exhibit 42: Number of Independent Pharmacies, 2001 to 2020

Exhibit 43: Pharmacy Franchise and Marketing Programs, 2020

Exhibit 44: Share of Mail Pharmacy Dispensing Revenues, by Company, 2020

Exhibit 45: Importance of Specialty Pharmacy Services to Patients, 2020

Exhibit 46: Usage of Specialty Pharmacy Services by Patients, 2018 vs. 2020

Exhibit 47: Specialty Prescription Dispensing Revenues, Annual Total and Growth, 2016 to 2020

Exhibit 48: Specialty Drugs As a Percentage of Pharmacy Industry Prescription Revenues, 2013 to 2019

Exhibit 49: Specialty Drugs As a Percentage of Payers’ Pharmacy Benefit Spending, by PBM, 2013 vs. 2019

Exhibit 50: Number of Pharmacy Locations With Specialty Pharmacy Accreditation, by Organization, 2015 to 2020

Exhibit 51: Locations With URAC Specialty Pharmacy Accreditation, 2008 to 2020

Exhibit 52: Prescription Revenues and Market Share from Specialty Pharmaceuticals, by Company, 2020

Exhibit 53: Merger and Acquisition Transactions, Specialty Pharmacy and Infusion Services, 2014 to 2020

Exhibit 54: Pharmacy Locations With Specialty Pharmacy Accreditation, by Corporate Ownership, 2020

Exhibit 55: Share of Pharmacy Locations With Specialty Pharmacy Accreditation, by Corporate Ownership, 2015 vs. 2020

Exhibit 56: Specialty Drug Prescription Revenues, by Dispensing Format, 2020

Exhibit 57: Number of Private Specialty Pharmacies Ranked on Inc. 5000 List, 2012 to 2020

Exhibit 58: Retail Companies With Specialty Pharmacy Businesses, 2020

Exhibit 59: Hospitals With a Specialty Pharmacy, by Number of Staffed Beds, 2015 vs. 2019

Exhibit 60: Prescription Dispensing Revenues from Specialty Pharmacy, by Health System, 2020

Exhibit 61: Health Systems’ Requirements for Employee Use of an In-House Pharmacy, 2020

Exhibit 62: Percentage of Oncology Practices With In-Practice Oral Oncology Drug Dispensing, 2013 to 2018

Exhibit 63: Frequency of Manufacturer Contracting for Specialty Pharmacy Services, by Type of Service, 2019

Exhibit 64: Example of Specialty Hub Workflow

Exhibit 65: Leading Specialty Hub Services Providers and Ownership, 2020

Exhibit 66: Chapter Coverage of Flows in the U.S. Distribution and Reimbursement System

Exhibit 67: Comprehensive Health Insurance Enrollment, by Payer, 2018 to 2020

Exhibit 68: Change in Membership, Commercial vs. Managed Medicaid, by Insurer, 2020
Exhibit 101: Distribution of Cost Sharing Formulas for Prescription Drug Benefits in Employer-Sponsored Plans, by Plan Type, 2020 ................................................................. 168
Exhibit 102: Type of Cost Sharing for Prescription Drug Benefits, Employer-Sponsored Plans Without High Deductibles, by Benefit Tier, 2020 .................................................. 169
Exhibit 103: Type of Cost Sharing for Prescription Drug Benefits, Employer-Sponsored Plans With High Deductibles, by Benefit Tier, 2020 .......................................................... 169
Exhibit 104: Average Cost Sharing by Prescription Drug Tier, Employer-Sponsored Plans, 2020 .............................. 170
Exhibit 105: Distribution of Coinsurance Structures for Prescription Drug Benefits, Employer-Sponsored Plans, Fourth and Specialty Tiers, 2020 ........................................................................ 171
Exhibit 106: Percentage of Covered Workers With a Separate Prescription Drug Deductible, by Plan Type, 2019 .172
Exhibit 107: Percentage of Covered Workers With Pharmacy Benefit Deductibles, Employer-Sponsored Plans, 2005 to 2020......................................................... 172
Exhibit 108: Type of Cost Sharing for Prescription Drug Benefits, Silver Health Insurance Marketplace Plans, 2019 .............................................................. 174
Exhibit 109: Average Cost Sharing by Prescription Drug Tier, Silver Health Insurance Marketplace Plans, 2020....174
Exhibit 110: Presence of Separate Prescription Drug Deductibles in Silver Plans on Health Insurance Marketplaces, 2014 to 2020................................................................................ 175
Exhibit 111: Medicare Part D Enrollment, by Type of Plan, 2010 to 2019 ................................................................. 176
Exhibit 112: Standard Medicare Prescription Drug Benefit, 2020 .............................................................................. 177
Exhibit 113: Distribution of Cost Sharing Formulas for Medicare Part D Plans, 2020 ........................................................ 178
Exhibit 114: Median Copayments by Prescription Drug Tier, Medicare Part D PDPs, 2020........................................... 178
Exhibit 115: Median Cost Sharing by Prescription Drug Tier, Medicare Advantage Plans, 2020 ............................... 179
Exhibit 116: Distribution of Coinsurance Rates for Specialty Drugs, Medicare Part D Plans, 2019......................... 179
Exhibit 117: Median Cost Sharing Amounts for 20 Largest Medicare Part D Plans, 2020............................................. 180
Exhibit 118: Manufacturer Spending on Copay Offset Programs, 2010 to 2019.......................................................... 182
Exhibit 119: Prevalence of Copayment Offset Programs for Specialty Drugs, 2016 vs. 2020 ................................. 183
Exhibit 120: Share of Patients Using Manufacturer Cost sharing Assistance for Specialty Drugs, by Therapy, 2015 vs. 2019....................................................................................... 183
Exhibit 121: Maximum Annual Benefit for Copayment Offset Programs, by Specialty Therapy Class, 2020........184
Exhibit 122: Large Employers’ Tactics for Managing Copay Offset Programs, 2019 to 2021 ................................. 185
Exhibit 123: Employer Views on Copayment Assistance Programs, 2019 ................................................................. 185
Exhibit 124: Pharmacist Views on Copayment Assistance Programs, 2020 ............................................................. 186
Exhibit 125: Copay Accumulator Adjustment and Copay Maximizers, Prevalence and Use in Commercial Insurance, 2018 to 2021 ................................................................................ 188
Exhibit 126: Pharmaceutical Manufacturer Charitable Foundations, by Total Giving, 2018................................. 192
Exhibit 127: Per Capita Out-of-Pocket Spending on Outpatient Prescription Drugs, 2010 to 2019 ...................... 193
Exhibit 128: Consumers’ Out-of-Pocket Spending Share of Outpatient Prescription Drug Expenditures, 1965 to 2019 193
Exhibit 129: Average Per-Prescription Patient Out-of-Pocket Costs, by Type of Prescription, 2015 vs. 2019 .......194
Exhibit 130: Distribution of Annual Patient Out-of-Pocket Spending, by Type of Health Plan, 2019.................195
Exhibit 131: Cost Sharing Waived for Medication to Treat Chronic Conditions, by Company Size, 2020...............196
Exhibit 132: Type of Cost Sharing for Out-of-Pocket Prescription Spending, 2015 to 2019.................................197
Exhibit 133: Type of Cost Sharing for Out-of-Pocket Prescription Spending on Specialty Drugs, by Therapy and Average Cost, 2019 ................................................................................................................198
Exhibit 134: Medicare Part D, Share of Benefit Liability, by Payer, 2007 vs. 2017..................................................199
Exhibit 136: Consumer Understanding of Health Insurance Terms, 2019..........................................................201
Exhibit 137: CVS Health, Quarterly Retail Prescription Revenues, 2014 to 2020 ..............................................202
Exhibit 138: Summary of Pharmacy Benefit Network Design Options ..............................................................204
Exhibit 139: Average Distance to Nearest Pharmacy, by Core Based Statistical Area (CBSA) Status, 2017 ........205
Exhibit 140: Medicare Part D PDPs With Preferred Pharmacy Networks, 2011 to 2021 .................................209
Exhibit 141: Participation As a Preferred Cost Sharing Pharmacy in Selected Medicare Part D PDPs, by Retail Chain, 2021 ..................................................................................................................211
Exhibit 142: Enrollment in Medicare Part D PDPs with Preferred Cost Sharing Networks, by Pharmacy Chain, 2020 vs. 2021 ..........................................................................................................................212
Exhibit 143: Participation As a Preferred Cost Sharing Pharmacy in Selected Medicare Part D PDPs, by PSAO, 2021 ..........................................................................................................................214
Exhibit 144: Share of Large Employers with a Narrow Retail Pharmacy Network, 2013 to 2020 ...............216
Exhibit 145: Mandatory Mail Pharmacy Utilization for Maintenance Medications, Employer-Sponsored Plans, 2013 to 2018 .................................................................................................................218
Exhibit 146: TRICARE, Net Spending on Outpatient Prescriptions, by Dispensing Outlet, 2012 to 2019 ........219
Exhibit 147: Payers’ Perceived Lowest-Cost Site of Care for Specialty Dispensing, 2018 .............................220
Exhibit 148: Share of Large Employers with Restricted Specialty Pharmacy Network, by Network Size, 2011 to 2020 .......................................................................................................................221
Exhibit 149: Drug Sourcing for Infused Therapies, Oncology vs. Non-Oncology, by Practice Type and Source, 2019 .................................................................................................................................223
Exhibit 150: Payer Methodologies for Computing a Pharmacy’s Estimated Acquisition Cost .......................229
Exhibit 151: Pharmacy AWP Reimbursement and Copayments for Brand-Name Prescriptions, by Dispensing Format, 2020 ......................................................................................................................232
Exhibit 152: AWP Reimbursement Difference, Retail vs. Mail Pharmacies, 2008 to 2020 ..........................233
Exhibit 154: AWP Reimbursement and Copayments for Generic Prescriptions, by Dispensing Format, 2020 ....236
Exhibit 155: Pharmacy Reimbursement in Medicaid, Fee-for-Service vs. Managed Care ...............................239
Exhibit 156: Pharmacy Reimbursement Methodology and Dispensing Fee, Largest Fee-for-Service State Medicaid Programs, 2020 ..................................................................................................................241
Exhibit 157: PBM Rebate Arrangements for Traditional and Specialty Medications in Employer-Sponsored Plans, by Employer Size, 2020 ........................................................................................................243
Exhibit 158: Total PBM-Negotiated Rebates and Share Retained, Diabetes Drugs in Nevada, 2017 to 2019
Exhibit 159: PBM Administrative Fees as Percentage of WAC, by Company, 2019
Exhibit 160: Value of Direct and Indirect Remuneration (DIR) in Medicare Part D, 2012 to 2020
Exhibit 161: Medicare Part D, Value of Direct and Indirect Remuneration (DIR), by Source, 2013 vs. 2020
Exhibit 162: Medicaid Program, Gross Prescription Spending and Prescriptions, Fee-For-Service vs. Managed Care, 2015 vs. 2019
Exhibit 163: Largest Managed Medicaid Organizations, By Enrollment, 2020
Exhibit 164: Medicaid, Gross vs. Net Spending on Outpatient Drugs, 2015 to 2019
Exhibit 165: Brand-Name Drugs, Change in Average List and Net Prices, 2014 to 2020
Exhibit 166: Change in List vs. Net Price, by Manufacturer, 2019
Exhibit 167: Total Value of Pharmaceutical Manufacturers’ Gross-to-Net Reductions for Brand-Name Drugs, 2014 to 2020
Exhibit 168: Total Value of Pharmaceutical Manufacturers’ Gross-to-Net Reductions for Brand-Name Drugs, by Source, 2020
Exhibit 169: CVS Health, Brand-Name Rebates Per Commercial Life and Share Retained by PBM, 2011 to 2020
Exhibit 170: Large Employers’ Point-of-Sale Rebate Programs, 2019 to 2021
Exhibit 171: Prescription Economics for a Third-Party Payer—Traditional Brand-Name Drug Example
Exhibit 172: Prescription Economics for a Third-Party Payer—Traditional Brand-Name Drug Example in a High-Deductible Health Plan
Exhibit 173: Prescription Economics for a Third-Party Payer—Traditional Brand-Name Drug Example in High-Deductible Health Plan with Point-of-Sale Rebates
Exhibit 174: Prescription Economics for a Third-Party Payer—Specialty Brand-Name Drug Example
Exhibit 175: U.S. Drug Distribution and Related Revenues at Big Three Wholesalers, 2020
Exhibit 176: Determination of a Pharmacy’s Brand-Name Drug Acquisition Cost from a Wholesaler
Exhibit 177: Pharmacy Buying Groups and Primary/Preferred Wholesaler Relationships, by Number of Pharmacies, 2020
Exhibit 178: Share of U.S. Generic Purchasing Volume, by Organization, 2020
Exhibit 179: Overall Gross Margins for Chain and Independent Drugstores, 2006 to 2019
Exhibit 180: Total Gross Profits for Chain and Independent Drugstores, 2015 to 2020
Exhibit 181: Overall Gross Margins for Chain and Independent Drugstores, by Company, 2020
Exhibit 182: Prescriptions As a Percentage of Revenues, Big Three Chain Drugstores, 2013 to 2020
Exhibit 183: Components of Overall Average Pharmacy Cost of Dispensing, 2019
Exhibit 184: Example of Brand-Name Prescription Economics for a Retail Pharmacy
Exhibit 185: Independent Pharmacies, Average Per-Prescription Gross Profits and Margins, 2015 to 2019
Exhibit 186: Diplomat Pharmacy, Average Per-Prescription Gross Profits and Margins, 2014 to 2019
Exhibit 187: Top Three PBMs, Sources of Gross Profit, 2015 vs. 2020
Exhibit 188: Illustrative Effect of Brand-Name List Price Increases on a Prescription’s Gross Profit
Exhibit 189: Median Generic Price Relative to Brand Price Before Generic Entry, by Number of Manufacturers
Exhibit 190: imatinib mesylate, Pharmacy Acquisition Cost, Brand vs. Generic, 2016 to 2021
Pre-publication draft (2/15/21) – Subject to change
Exhibit 191: Lifecycle of Per-Prescription Gross Profits, Brand vs. Multisource Generic ........................................... 301
Exhibit 192: Median AWP Discount for Generic Drugs Sold to Retail Pharmacies, by Number of Manufacturers, 2020 ................................................................. 303
Exhibit 193: Net Value of Pharmacy DIR Fees in Medicare Part D, 2013 to 2020 ................................................................. 306
Exhibit 194: 340B Drug Pricing Program, Purchases by Covered Entities, 2014 to 2020 ...................................................... 310
Exhibit 195: 340B Contract Pharmacy Locations, 2010 to 2020 ....................................................................................... 311
Exhibit 196: 340B Covered Entities, By Number of Contract Pharmacies, 2020 ................................................................. 312
Exhibit 197: 340B Contract Pharmacy Locations, by Company, 2020 ............................................................................. 313
Exhibit 198: 340B Contract Pharmacy Locations, by Chain, 2013 vs. 2019 ................................................................. 313
Exhibit 200: Flow of Funds and Product for a 340B Contract Pharmacy Network ........................................................ 316
Exhibit 201: 340B Prescription Economics for a Covered Entity, a Contract Pharmacy, and a Patient—Specialty
Brand-Name Drug Example .................................................................................................................................................. 319
Exhibit 202: Total Gross Profits from 340B Contract Pharmacy, By Company, 2020 ............................................................. 321
Exhibit 203: Actual and Projected Growth Rates in National Health and Outpatient Prescription Drug Expenditures,
2015 to 2025 ........................................................................................................................................................................ 323
Exhibit 204: Change in Outpatient Visits, by Payer, 2020 ................................................................................................. 324
Exhibit 205: Total Brand Revenues Lost to Generic Launches, by Product Type, 2014 to 2024 ................................. 325
Exhibit 206: Pharmacy Industry Prescription Revenues, Traditional vs. Specialty Drugs, 2015 to 2025 ................. 326
Exhibit 207: Average Year-Over-Year Change in Pricing of Mature Generic Drugs, Oral vs. Injectable, 2015 to 2020
.......................................................................................................................................................................................... 329
Exhibit 208: Generic Drug Approvals, FDA, 2014 to 2020 ................................................................................................. 330
Exhibit 209: Number of U.S. Biosimilar Approvals, 2015 to 2020 ................................................................................. 332
Exhibit 210: Vertical Business Relationships Among Insurers, PBMs, Specialty Pharmacies, and Providers, 2021 .. 336
Exhibit 211: Venture Capital-Backed Digital Pharmacies and Total Funding, 2021 .......................................................... 352